Shen Guomiao, Behera Digambar, Bhalla Manpreet, Nadas Arthur, Laal Suman
Department of Pathology, New York University School of Medicine, New York, NY 10010, USA.
Clin Vaccine Immunol. 2009 Jan;16(1):49-54. doi: 10.1128/CVI.00334-08. Epub 2008 Nov 12.
Tuberculosis (TB) is a major cause of morbidity and mortality, especially in developing countries. Despite significant limitations, microscopy remains the cornerstone of the global TB control strategy. As the TB epidemic escalates, new diagnostic methods that are accurate and also economical and simple to manufacture and deploy are urgently needed. Although several promising antigens have been identified and evaluated in recent years, the reproducible production of high-quality recombinant mycobacterial proteins with minimal batch-to-batch variation is difficult, laborious, and expensive. To determine the feasibility of devising a synthetic peptide-based diagnostic test for TB, we have delineated the immunodominant epitopes of three candidate antigens, Ag85B, BfrB, and TrxC, that were previously identified to be immunogenic in TB patients. The results demonstrate that combinations of carefully selected synthetic peptides derived from highly immunogenic proteins can be the basis for devising an immunodiagnostic test for TB.
结核病(TB)是发病和死亡的主要原因,在发展中国家尤为如此。尽管存在显著局限性,但显微镜检查仍是全球结核病控制策略的基石。随着结核病疫情的升级,迫切需要准确、经济且易于生产和部署的新诊断方法。尽管近年来已鉴定并评估了几种有前景的抗原,但以最小的批次间差异可重复生产高质量重组分枝杆菌蛋白既困难、费力又昂贵。为了确定设计基于合成肽的结核病诊断测试的可行性,我们已描绘出三种候选抗原Ag85B、BfrB和TrxC的免疫显性表位,这些抗原先前已被确定在结核病患者中具有免疫原性。结果表明,源自高免疫原性蛋白的精心挑选的合成肽组合可成为设计结核病免疫诊断测试的基础。